On April 16, 2024, the Cambridge, UK-based AI biotech startup Qureight announced it has raised $8.5 million in Series A funding, led by Hargreave Hale AIM VCT, with participation from XTX Ventures, Guinness Ventures, Playfair Capital, Meltwind, Ascension Life Fund, and Cambridge Angels.
Founded in 2018, Qureight uses a proprietary AI platform to help accelerate the drug development process by improving the efficiency of clinical trials and data analysis. Qureight organizes valuable medical data in one place for AI models to analyze, helping researchers make smarter decisions faster than analyzing results on their own.
(Source:Sifted）